Benefits of immunotherapy in hepatocellular carcinoma are confirmed in Asian subpopulations
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
New subpopulation analyses from three international phase III trials confirm efficacy of immune checkpoint inhibitors across geographical areas
Positive results in intermediate and advanced disease come after the failure of global trials investigating the combination of TACE with targeted agents
Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach
Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up
Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer
Although not immediately practice-changing, impressive results from the NICHE-2 trial may open a way to a ‘watch and wait’ approach for some patients
Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma
Disease-free and overall survival in the PRODIGE-24/CCTG PA6 study were significantly higher in GemPred-positive versus GemPred-negative patients who received adjuvant gemcitabine
Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.